Respiratory Analytics

Based in the UK, Respiratory Analytics, operates as a developer of digital tools for inhaler monitoring and airway disease management. Founded in 2019, Respiratory Analytics develops innovative solutions for respiratory health. This funding is part of a larger GBP 1. 2 million equity and grant funding round, aimed at supporting FDA clearance, clinical studies, team growth, health-economic evidence, and initial market entry for asthma treatments.

Respiratory Analytics specializes in a proprietary digital platform designed to enhance inhaler use for patients with respiratory conditions. Their flagship product, the aflo™ smart inhaler system, includes a connected inhaler sensor, a patient app, and a clinician portal, providing real-time feedback to improve self-management of asthma and Chronic Obstructive Pulmonary Disease (COPD). The revenue model for Respiratory Analytics is based on subscriptions and partnerships with healthcare providers. The company collaborates with healthcare professionals and respiratory clinics to integrate the aflo™ platform into patient care, facilitating ongoing access to the technology and tailored data insights.

Additional revenue may arise from clinical studies leveraging the aflo™ technology. The company plans to utilize the recent funding to support FDA clearance and clinical studies, while also focusing on team growth and establishing health-economic evidence. Current initiatives include initial market entry for asthma treatments.